Company: BFRG
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023560
Chunk: 60

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 8
Chunk 60
---
 business using funds from our initial public offering and subsequent financings, have entered into partnerships
and relationships, completed our first commercial service contract with a leading rare disease non-profit organization for AI/ML analysis
of late-stage clinical data in 2023, and we are partway through our collaboration agreement for clinical trial optimization with a Phase
III oncology company focused on novel chemotherapeutic treatments for rare cancers. We have also acquired the rights to a series of preclinical
and early clinical drug assets from universities, as well as entered into a strategic collaboration with a world-renowned research institution
to create a HSV1 viral therapeutic platform to engineer immunotherapies for a variety of diseases. We have signed exclusive worldwide
license agreements with Johns Hopkins University (“JHU”) for a cancer drug that targets glioblastoma (brain cancer), pancreatic
cancer, and others. We have also signed an exclusive worldwide license from George Washington University for another cancer drug that
targets hepatocellular carcinoma (liver cancer) and other liver diseases. In addition, we signed three-year strategic data and commercialization
agreements with the Lieber Institute for Brain Development (“LIBD”) whom we believe has a repository of the largest collection
of postmortem brains in the world, including molecular, clinical, and other data. The objective of this collaboration with LIBD is for
the Company to analyze these rich data sets using its proprietary AI/ML tools and models and then go to market with the discoveries with
the ultimate goal of securing revenue generating strategic partnership deals with biopharmaceutical companies. We intend to secure the
rights to other proprietary data sets and repeat this strategy. Additionally, we intend to gain access to later-stage clinical assets
through partnerships or the acquisition of rights to failed therapeutic candidates for drug rescue. In certain circumstances, we intend
to conduct late-stage clinical trials in an effort to rescue therapeutic assets that previously failed. In these cases, there will be
a requirement for drug supply and regulatory services to conduct clinical trials. The success of our clinical development programs will
require finding partners to support the clinical development, adequate availability of raw materials and drug product for our research
and development and clinical trials, and, in some cases, may also require the establishment of third-party arrangements to obtain finished
drug product that is manufactured appropriately under good manufacturing practices, and packaged for clinical use or sale. Since we are
a company focused on using our AI/ML technology to advance medicines, any clinical development programs will also require,